Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Short term Debt (2020 - 2021)

Rein Therapeutics (RNTX) has disclosed Short term Debt for 2 consecutive years, with $329000.0 as the latest value for Q1 2021.

  • Quarterly Short term Debt changed N/A to $329000.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $329000.0 through Mar 2021, changed N/A year-over-year, with the annual reading at $168000.0 for FY2020, N/A changed from the prior year.
  • Short term Debt for Q1 2021 was $329000.0 at Rein Therapeutics, up from $168000.0 in the prior quarter.
  • The five-year high for Short term Debt was $329000.0 in Q1 2021, with the low at $48000.0 in Q3 2020.